Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00382265 · ClinicalTrials.gov registry record · Phase 4

Tamsulosin for Urolithiasis in the Emergency Dept

A Phase 4 study of Ureterolithiases, sponsored by Andrew Meltzer.

Completed
Registry status
Phase 4
Development phase
512
Enrollment target
4
Study locations

NCT00382265: Completed Phase 4 study of Ureterolithiases, sponsored by Andrew Meltzer.

NCT00382265 is a Phase 4 study of Ureterolithiases that has completed, run by Andrew Meltzer. The registered enrollment target is 512 participants, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target. The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00382265, a Phase 4 study of Ureterolithiases, has completed, sponsored by Andrew Meltzer.

COMPLETED
Registry status
Phase 4
Development phase
512 participants
Enrollment target
4
Study locations

Study Summary

Urolithiasis is a disease that effects 12% of the population and its incidence is growing. In the US there are over 1.1 million visits annually to Emergency Departments for renal colic. The disease is extremely painful, often requiring large amounts of narcotic analgesia, and results in lost work days. Moreover, up to 30% of patients may eventually require lithotripsy or surgical removal of the stone. Currently there are no medical interventions other than analgesia which are offered to patients. Based on encouraging results from several small European clinical studies, the researchers hypothesize that the administration of tamsulosin to patients with symptomatic urolithiasis will enhance stone passage, and reduce both the time to recovery and the need for surgical intervention or lithotripsy. The researchers will conduct a study by identifying and recruiting patients presenting with urolithiasis in the emergency departments of four institutions. A total of 500 consenting subjects will be randomly assigned to one of two groups: 1. tamsulosin for a maximum of 28 days; 2. placebo for a maximum of 28 days. In addition, both groups will receive standard analgesic therapy. The study team, which will be blinded to treatment status, will monitor each subject's clinical progress and outcome. The primary objectives of this study are: 1. to determine if tamsulosin is effective, and 2. to evaluate the safety of the therapy. Another objective is to identify the most appropriate clinical subgroup(s) for treatment. If the therapeutic benefits observed in smaller clinical studies are replicated, administration of these medications should produce several benefits, including: 1. a reduction in time to pain free recovery and hence a more rapid return to employment; 2. decreased requirements for narcotic analgesia; 3. less need for urological out-patient clinic follow-up; 4. decreased need for surgical intervention or lithotripsy; and 5. substantial cost savings. If this the

Primary Outcome

Hypothesis: The administration of tamsulosin after the clinical and radiographic diagnosis of acute urolithiasis will produce an increase in the proportion of patients passing their stone within 28 days.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG tamsulosin

Study Locations (4)

Pennsylvania

  • Thomas Jefferson University - Philadelphia
  • University of Pittsburgh - Pittsburgh

Alabama

  • University of Alabama - Birmingham - Birmingham

District of Columbia

  • The George Washington University Medical Center - Washington D.C.

Trial Details

FieldValue
Enrollment Target 512 participants
Start Date 2008-01
Est. Completion 2017-02-01
Phase Phase 4
Andrew Meltzer

4 total trials

What the finished NCT00382265 record still lists

NCT00382265 is an interventional study that assigns participants to a tested intervention. The registered 512 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target.

The record links to 1 condition, with Ureterolithiases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00382265 reports a single indexed study location in Pennsylvania, Alabama, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00382265 about?

NCT00382265 is a clinical study titled "Tamsulosin for Urolithiasis in the Emergency Dept". Urolithiasis is a disease that effects 12% of the population and its incidence is growing. In the US there are over 1.1 million visits annually to Emergency Departments for renal colic. The disease is extremely painful, often requiring large amounts of narcotic analgesia, and results in lost work da...

What is the current status of trial NCT00382265?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 512 participants. The study started on 2008-01. Estimated completion is 2017-02-01.

What conditions does trial NCT00382265 study?

This clinical trial studies the following conditions: Ureterolithiases.

What interventions are being tested in trial NCT00382265?

The interventions under investigation include: Placebo (OTHER), tamsulosin (DRUG).

Who is sponsoring clinical trial NCT00382265?

This trial is sponsored by Andrew Meltzer, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00382265 being conducted?

This trial has 4 study locations across Alabama, District of Columbia, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT00382265's enrollment target sits among peer trials

512 161st of 2000 higher than 1,840 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05005403 · 512 participants · Phase 1

    Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab

  • NCT05337410 · 512 participants · NA

    YES: Innovative Discussion for Engagement, Achievement, and Service

  • NCT06096259 · 512 participants · Phase 2

    Preventing Injured Knees From osteoArthritis: Severity Outcomes

  • NCT05691244 · 514 participants · Phase 3

    Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00382265, the US trial registry maintained by the National Library of Medicine. NCT00382265 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.